DeepMed Research

Fate Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 220

Market Cap: $408.8M

Website

Clinical Trials

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1

Terminated

Conditions: Lymphoma, B-Cell
Chronic Lymphocytic Leukemia

Interventions: Drug: FT596
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine
Drug: Rituximab
Drug: Obinutuzumab

First Posted Date: 2020-01-29

Last Posted Date: 2023-10-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 98

Registration Number: NCT04245722

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 6 locations

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Terminated

Conditions: Colorectal Cancer
Squamous Cell Carcinoma
Pancreas Cancer
EGFR Positive Solid Tumor
Renal Cell Carcinoma
Melanoma
NSCLC
Microsatellite Instability
Advanced Solid Tumor
Lymphoma

Interventions: Genetic: Allogeneic natural killer (NK) cell

First Posted Date: 2019-09-26

Last Posted Date: 2023-09-21

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 20

Registration Number: NCT04106167

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
UCSD Moores Cancer Center, San Diego, California, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 1 locations

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

Terminated

Conditions: Hematological Malignancy

Interventions: Genetic: Genetically engineered NK cells

First Posted Date: 2019-09-18

Last Posted Date: 2022-08-29

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 2

Registration Number: NCT04093622

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States

and more 2 locations

FT516 in Subjects With Advanced Hematologic Malignancies

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
B-cell Lymphoma

Interventions: Drug: FT516
Drug: Rituximab
Drug: Obinutuzumab
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: IL-2
Drug: Bendamustine

First Posted Date: 2019-07-17

Last Posted Date: 2023-10-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 72

Registration Number: NCT04023071

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States

and more 4 locations

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cervical Cancer
Advanced Solid Tumors
EGFR Positive Solid Tumor
Hepatocellular Carcinoma
Renal Cell Carcinoma
NSCLC
Urothelial Carcinoma
Colorectal Cancer
Small Cell Lung Cancer
Melanoma

Interventions: Drug: FT500
Drug: Cyclophosphamide
Drug: Nivolumab
Drug: Pembrolizumab
Drug: Atezolizumab
Drug: Fludarabine
Drug: IL-2

First Posted Date: 2019-02-15

Last Posted Date: 2023-05-01

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 37

Registration Number: NCT03841110

Locations: 🇺🇸
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: HER2-positive Breast Cancer
Head and Neck Squamous Cell Carcinoma
Melanoma
HER2 Positive Gastric Cancer
Colorectal Cancer
EGFR Positive Solid Tumor
Advanced Solid Tumors
Hepatocellular Carcinoma
Non Small Cell Lung Cancer
Renal Cell Carcinoma

Interventions: Drug: FATE-NK100
Drug: Trastuzumab
Drug: Cetuximab

First Posted Date: 2017-10-24

Last Posted Date: 2021-11-22

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 44

Registration Number: NCT03319459

Locations: 🇺🇸
UCSD Moores Cancer Center, San Diego, California, United States
🇺🇸
The Ohio State University James Cancer Hospital, Columbus, Ohio, United States
🇺🇸
Baylor Scott & White Research Institute, Dallas, Texas, United States

and more 1 locations

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Acute Graft-versus-host Disease
Myelodysplastic Syndromes
Chronic Myelogenous Leukemia

Interventions: Biological: Control Arm
Biological: ProTmune

First Posted Date: 2016-04-19

Last Posted Date: 2023-02-08

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 96

Registration Number: NCT02743351

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Indiana Blood and Marrow Transplant, Indianapolis, Indiana, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 12 locations

A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders

Phase 1

Terminated

Conditions: Metabolic Disorders

Interventions: Biological: ProHema-CB Transplant

First Posted Date: 2015-02-03

Last Posted Date: 2018-10-10

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 1

Registration Number: NCT02354443

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

Phase 1

Terminated

Conditions: Hematologic Malignancies

First Posted Date: 2015-02-03

Last Posted Date: 2018-10-10

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 3

Registration Number: NCT02354417

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
City of Hope, Duarte, California, United States

The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

Phase 2

Terminated

Conditions: Hematologic Malignancies

Interventions: Biological: ProHema-CB
Biological: Untreated CB

First Posted Date: 2012-06-25

Last Posted Date: 2021-11-30

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 62

Registration Number: NCT01627314

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute- Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy